Products for Research Use Only
RegisterLogin

FD274

CAT: 0804-HY-155066-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-155066-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
FD274 is a highly potent PI3K/mTOR dual inhibitor with IC50s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. FD274 exhibits significant anti-proliferation of AML cell lines (HL-60 and MOLM-16) . FD274 arrests HL-60 cell cycle at G1 phase and increases apoptosis. FD274 demonstrates dose-dependent inhibition of tumor growth in the HL-60 xenograft model. FD274 has the potential for acute myeloid leukemia research[1].
CAS Number
2641899-38-7
UNSPSC
12352005
Target
Apoptosis; mTOR; PI3K
Type
Reference compound
Related Pathways
Apoptosis; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fd274.html
Purity
99.45
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
ClC1=NC=C(C2=CN=C(NN=C3C4=CC=NC=C4)C3=C2)C=C1NS(=O)(C5=CC=C(F)C=C5)=O
Molecular Formula
C22H14ClFN6O2S
Molecular Weight
480.90
References & Citations
[1]Chengbin Yang, et al. Discovery of N- (2-chloro-5- (3- (pyridin-4-yl) -1H-pyrazolo[3,4-b]pyridin-5-yl) pyridin-3-yl) -4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. 2023 Oct 5;258:115543.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MTOR; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ

Alternative Products

CatalogName
GTR19214423-01FD274

Popular Products